ImageneBio Inc Dossier - Source-backed chat

ImageneBio Inc

IMANASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.81

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $4.58Price as of 1 Oct 2026

Data confidence Sign in to view data confidence

Market Cap $52.1M

Shares Outstanding 11.4M diluted

Next Earnings Date16 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

ImageneBio, Inc. (Nasdaq: IMA) is a clinical-stage biopharmaceutical company formed via the July 2025 merger of Ikena Oncology and Inmagene Biopharmaceuticals. The company is entirely focused on its lead asset, IMG-007, a novel, non-depleting, ADCC-silenced anti-OX40 monoclonal antibody with an extended half-life. While early Phase 1b/2a data in atopic dermatitis and alopecia areata show promising efficacy and a highly differentiated safety profile (no reports of pyrexia or chills), the company is currently in a catalyst-light period. The primary value-inflection milestone—topline data from the Phase 2b ADAPTIVE trial in atopic dermatitis—is not expected until Q4 2027. Although a recent $30 million private placement in April 2026 extended the cash runway into Q1 2028, the high single-asset risk, lack of near-term clinical catalysts, and intense competitive landscape from established biologics and other OX40/OX40L inhibitors justify a Hold rating at this stage.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$24.00

Mean target$24.00

High · most bullish analyst$24.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$2.0020%

The Phase 2b ADAPTIVE trial experiences enrollment delays, pushing topline data into 2028 and forcing the company to raise highly dilutive capital under unfavorable market conditions. Alternatively, safety signals (such as pyrexia) emerge in the larger patient cohort, or efficacy fails to differentiate from existing biologics like Dupixent or competing OX40/OX40L programs.

Base CaseCentral scenario

$13.0055%

The Phase 2b ADAPTIVE trial progresses on schedule with topline results in Q4 2027 confirming competitive efficacy and safety. The cash runway remains sufficient to reach these key readouts, but the stock trades sideways or experiences moderate volatility due to the lack of near-term clinical catalysts.

Bull CaseUpside scenario

$24.0025%

IMG-007 demonstrates superior efficacy and safety in the Phase 2b ADAPTIVE trial, showing best-in-class potential with a highly convenient dosing schedule (e.g., every 12 or 24 weeks) and zero pyrexia. Rapid enrollment in the alopecia areata Phase 2 trial accelerates development timelines, attracting a major pharmaceutical partner and driving significant valuation expansion.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated Mechanism of Action: IMG-007 is bioengineered to block OX40/OX40L signaling without depleting T cells (ADCC-silenced), avoiding the pyrexia and chills associated with T-cell depleting agents.
Extended Half-Life: A terminal half-life of approximately 35 days supports highly competitive, convenient dosing regimens (potentially quarterly or every 24 weeks for maintenance).
Strong Financial Backing: Supported by prominent healthcare investors (e.g., Coastlands Capital, OrbiMed, Omega Funds) with a cash runway extending into Q1 2028.

Key Investment Risks

High Single-Asset Concentration: The company's pipeline is heavily dependent on the clinical and commercial success of a single asset, IMG-007.
Catalyst-Light Period: The primary clinical readout (Phase 2b ADAPTIVE) is not expected until Q4 2027, leaving a long window without major value-inflection events.
Intense Competitive Landscape: Faces strong competition from approved blockbusters (e.g., Dupixent) and advanced clinical-stage OX40/OX40L programs (e.g., Sanofi's amlitelimab, Amgen's rocatinlimab).

Thesis Invalidation Triggers

Failure to meet the primary endpoint (percent change in EASI at 24 weeks) in the Phase 2b ADAPTIVE trial.
Emergence of significant safety concerns, such as high rates of pyrexia, chills, or other severe adverse events in the expanded Phase 2b cohort.
Severe enrollment delays in the ADAPTIVE trial or the planned Phase 2 alopecia areata trial that push data readouts beyond current runway limits.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.